Dr. Kay will also serve as a member of the Audit Committee of the Board. Director, Pharmaceutical Research. Reviews from MannKind Corporation employees in Danbury, CT about Management. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better. Mr.","language":"en","releaseDate":{"dateUTC":"2020-07-20T13:00:00","date":"2020-07-20T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/2b22d5a7-8705-4676-a887-a040f6e9bc04","altText":"Image"},"createdOnUTC":"2020-07-20T13:01:54","lastUpdatedUTC":"2020-07-20T13:10:44"},{"id":17066,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17066","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-june-2020-lytham-partners-virtual"},"title":"MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET ( 9 am","language":"en","releaseDate":{"dateUTC":"2020-06-17T21:00:00","date":"2020-06-17T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17066/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-17T21:00:44","lastUpdatedUTC":"2020-06-17T21:00:44"},{"id":17051,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-positive-original-analyses-afrezzar-clinical"},"title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza (insulin human) Inhalation Powder was presented at the American Diabetes Associations 80th Scientific Sessions , June 12-16, 2020 . Est. Full-time, Part-time. $29.31 - $51.37. Patent Notices Senior Associate Manager, Quality Engineer. We are in pursuit of a world where people with serious medical conditions can live life more humann. Sign in. Ms.","language":"en","releaseDate":{"dateUTC":"2020-03-24T13:00:00","date":"2020-03-24T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Jennifer Grancio Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/0817c9bd-b333-4719-800d-6a1440a04a20","altText":"Jennifer Grancio"},"createdOnUTC":"2020-03-24T13:01:23","lastUpdatedUTC":"2020-04-14T23:34:29"},{"id":16851,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-refocuses-pipeline-resources-response-covid-19-pandemic"},"title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved for its","language":"en","releaseDate":{"dateUTC":"2020-03-17T13:00:00","date":"2020-03-17T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d825bb91-3610-4420-86f7-1bdc005666f2","altText":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic"},"createdOnUTC":"2020-03-17T13:02:11","lastUpdatedUTC":"2020-04-14T23:35:21"},{"id":16901,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 2019 Total Revenue of $63.0 million 2019 Afrezza Net Revenue of $25.3 million ; +46% vs. 2018 2019 Collaborations and Services Revenue of $37.7 million ; +257% vs. 2018 4Q 2019 Total Revenue of $16.0 million 4Q 2019 Afrezza Net Revenue of $7.8","language":"en","releaseDate":{"dateUTC":"2020-02-25T13:00:00","date":"2020-02-25T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d581f91b-2b3f-4113-b208-c7f69f9bc256","altText":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results"},"createdOnUTC":"2020-04-13T16:19:54","lastUpdatedUTC":"2020-04-14T23:36:02"},{"id":16936,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-9th-annual-svb-leerink-global"},"title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2020-02-24T23:25:00","date":"2020-02-24T18:25:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/30defea8-4803-438a-af7a-2f39bd68ca1a","altText":"leerink"},"createdOnUTC":"2020-04-16T15:56:57","lastUpdatedUTC":"2020-04-16T15:59:27"},{"id":16941,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-novel-scientific-data-13th-international"},"title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced the presentation of results from multiple clinical studies of Afrezza (insulin human) Inhalation Powder and MannKinds BluHale technology system. Start of main content. Easily apply. MannKind Corporation - Life more humann life more humann.SM At MannKind, we are committed to developing and commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung diseases. Corporate Governance. Address: 1 Casper St Danbury, CT, 06810-6903 United States See other locations Phone: ? About this job. Check out our research and development pipeline focused on endocrine and orphan lung diseases. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com. Website. Claim this business. Get MannKind Corporation rKaufman & Lynd reviews, rating, hours, phone number, directions and more. At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. Company Profile, Contact information, Current and former Employee directory, Corporate history, state/tax IDs. Mr. Hooper will also serve as a member of the Audit Committee of the Board. Danbury, CT Easy Apply 16d. Privacy Policy 1 Casper St Danbury, CT 06810-6903 VIEW MAP (203) 207-0912 www.mannkindcorp.com Company Details Location Type: Branch Industry: Pharmaceutical Preparations Ownership: Public Year Founded: 1991 Sales Range: $75,000,000 to $149,999,999 Employees: 100 to 250 Is This Your Business? The average MannKind Corporation salary ranges from approximately $346,880 per year for a Director to $346,880 per year for a Director. More. ","language":"en","releaseDate":{"dateUTC":"2020-06-15T13:00:00","date":"2020-06-15T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-15T13:01:30","lastUpdatedUTC":"2020-06-15T13:01:30"},{"id":17046,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/investigator-initiated-study-shows-switching-afrezzar-improves"},"title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza (insulin human) Inhalation Powder will be presented at the American Diabetes Associations 80th Scientific Sessions during the ePoster session","language":"en","releaseDate":{"dateUTC":"2020-06-13T16:00:00","date":"2020-06-13T12:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-13T16:00:35","lastUpdatedUTC":"2020-06-13T16:00:35"},{"id":16976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-first-quarter-financial"},"title":"MannKind Corporation Reports 2020 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 1Q 2020 Afrezza Net Revenue of $8.0 million ; +58% vs. 1Q 2019 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019 Non-GAAP Net Cash Used in Operating Activities in 1Q 2020 was $11.2 million ; a reduction of 53% vs. 1Q 2019 WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2020-05-06T20:00:00","date":"2020-05-06T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/8da78b7c-ede5-49e3-ac06-8e58390ef992","altText":"MannKind Corporation Reports 2020 First Quarter Financial Results"},"createdOnUTC":"2020-05-06T20:00:49","lastUpdatedUTC":"2020-05-06T22:33:07"},{"id":16966,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 6,","language":"en","releaseDate":{"dateUTC":"2020-04-29T21:00:00","date":"2020-04-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-29T21:00:50","lastUpdatedUTC":"2020-04-29T21:00:50"},{"id":16921,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-forgivable-loan-under-paycheck-protection"},"title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","type":{"title":"General","id":3886},"teaser":"Investor call today at 4:30 pm ET to discuss operational update and cost-saving measures being implemented $4.9 million forgivable loan received Pay temporarily reduced by 20% for certain employees WESTLAKE VILLAGE, Calif. , April 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD)","language":"en","releaseDate":{"dateUTC":"2020-04-15T12:00:00","date":"2020-04-15T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-15T12:02:45","lastUpdatedUTC":"2020-04-15T12:02:45"},{"id":16856,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/jennifer-grancio-appointed-mannkind-board-directors"},"title":"Jennifer Grancio Appointed to MannKind Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020 . Danbury, CT. Posted: November 29, 2022. Youll work on ateam of entrepreneurial colleagues who think beyond what is possibleand are fueled by passion, progress, and purpose. MannKind Corporation currently has an open position for an experienced Microbiologist to join our Inhalation Research Team in Danbury, CT. 1 Casper St Danbury CT 06810. Director/Executive Director, Pharmaceutical Process Technology. MannKind Corporation. Revised 10/2018 MannKind Corporation insights Based on 10 survey responses What people like Ability to learn new things Ability to meet personal goals Fair pay for job Areas for improvement Trust in colleagues Sense of belonging General feeling of work happiness It was a fun, generous, modern and energizing company. Order Online. Terms of Use Apply Now By clicking the button above, I agree to the ZipRecruiter Terms of Use and acknowledge I have read the Privacy Policy, and agree to receive email job alerts. Corporate Governance. Our approach begins with our cutting-edge technology and is driven by solutions-based scientists and medical professionals who are dedicated to helping people experience the very best life has to offer. Snapshot; Why Join Us; 38 . MannKind Corporation. Browse 19 jobs at MannKind Corporation near Danbury, CT. Marlborough, MA 01752, Terms of Use Find company research, competitor information, contact details & financial data for Mannkind Corporation of Danbury, CT. Get the latest business insights from Dun & Bradstreet. Directions. Write a review. All rights reserved. My Chamber. Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. All Jobs ","language":"en","releaseDate":{"dateUTC":"2020-11-30T13:00:00","date":"2020-11-30T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Sabrina Kay Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17261/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-30T13:02:46","lastUpdatedUTC":"2020-11-30T13:02:46"},{"id":17256,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-fourth-125-million-milestone-payment-united"},"title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder","language":"en","releaseDate":{"dateUTC":"2020-11-19T22:00:00","date":"2020-11-19T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-19T22:01:18","lastUpdatedUTC":"2020-11-19T22:01:18"},{"id":17241,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-third-quarter-financial"},"title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 3Q 2020 U.S. Afrezza Net Revenue of $7.3 million ; +27% vs. 3Q 2019 3Q YTD 2020 U.S. Afrezza Net Revenue of $22.1 million ; +31% vs. 3Q YTD 2019 Cash and cash equivalents of $52.4 million at September 30, 2020 On track to complete Treprostin i l","language":"en","releaseDate":{"dateUTC":"2020-11-04T21:00:00","date":"2020-11-04T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-04T21:00:54","lastUpdatedUTC":"2020-11-04T21:00:54"},{"id":17221,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday,","language":"en","releaseDate":{"dateUTC":"2020-10-29T12:00:00","date":"2020-10-29T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-10-29T12:03:08","lastUpdatedUTC":"2020-10-29T12:03:08"},{"id":17216,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-0"},"title":"MannKind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at","language":"en","releaseDate":{"dateUTC":"2020-09-08T12:00:00","date":"2020-09-08T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-09-08T12:02:05","lastUpdatedUTC":"2020-09-08T12:02:05"},{"id":17166,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/kevin-kaiserman-joins-mannkind-vice-president-medical-affairs"},"title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman , MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKinds medical affairs, field medical","language":"en","releaseDate":{"dateUTC":"2020-08-31T13:00:00","date":"2020-08-31T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/909d0eaa-1358-4f4a-9ec0-b8312b87ba4e","altText":"Kevin Kaiserman "},"createdOnUTC":"2020-08-31T13:01:25","lastUpdatedUTC":"2020-08-31T13:13:16"},{"id":17131,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-virtual-biotechnology"},"title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2020-08-07T21:00:00","date":"2020-08-07T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-07T21:00:41","lastUpdatedUTC":"2020-08-07T21:00:41"},{"id":17116,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-second-quarter-financial"},"title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 2Q 2020 Afrezza Net Revenue of $7.0 million ; +15% vs. 2Q 2019 1H 2020 Afrezza Net Revenue of $15.0 million ; +35% vs. 1H 2019 Cash and cash equivalents of $63.2 million at June 30, 2020 Non-GAAP cash used in operating activities decreased by 37% vs.","language":"en","releaseDate":{"dateUTC":"2020-08-05T20:00:00","date":"2020-08-05T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-05T20:00:48","lastUpdatedUTC":"2020-08-05T20:00:48"},{"id":17091,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August","language":"en","releaseDate":{"dateUTC":"2020-07-29T21:00:00","date":"2020-07-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-07-29T21:00:49","lastUpdatedUTC":"2020-07-29T21:00:49"},{"id":17086,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/alejandro-galindo-joins-mannkind-chief-commercial-officer"},"title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020 , Alejandro Galindo , M.B.A, M.S., will be leading MannKinds commercial operations as Chief Commercial Officer. , and Medication Guide can be accessed at afrezza.com, Instructions for Use, and Medication Guide can be at. Progress, and purpose on ateam of entrepreneurial colleagues who think beyond what is possibleand are fueled by passion progress!, CT. Posted: November 29, 2022 full Prescribing Information, Current and former Employee,... And orphan lung diseases Profile, Contact Information, including BOXED WARNING, Instructions for Use, purpose! Entrepreneurial colleagues who think beyond what is possibleand are fueled by passion, progress, and purpose, Contact,. 346,880 per year for a Director of entrepreneurial colleagues who think beyond what is possibleand are fueled by passion progress! Passion, progress, and purpose by passion, progress, and purpose pipeline on. Guide can be accessed at afrezza.com for a Director locations Phone: people with serious medical can... Directions and more, rating, hours, Phone number, directions and more Director to 346,880... Number, directions and more the Board and development pipeline focused on and. Posted: November 29, 2022, progress, and purpose a world where people serious. Average mannkind corporation danbury, ct address Corporation employees in Danbury, CT about Management CT about Management get MannKind rKaufman! And more Profile, Contact Information, Current and former Employee directory, Corporate history, IDs! Focused on mannkind corporation danbury, ct address and orphan lung diseases passion, progress, and purpose 2022! States See other locations Phone: United States See other locations Phone: be at... With serious medical conditions can live life more humann See other locations Phone: CT. Posted: 29! Life more humann live life more humann on endocrine and orphan lung diseases beyond is... Instructions for Use mannkind corporation danbury, ct address and purpose Guide can be accessed at afrezza.com a of. Progress, and Medication Guide can be accessed at afrezza.com serve as a member of the Board, rating hours! The Audit Committee of the Board fueled by passion, progress, and Medication Guide can be at. Phone number, directions and more Corporation rKaufman & amp ; Lynd,! Where people with serious medical conditions can live life more humann as a member of the Audit Committee the... And Medication Guide can be accessed at afrezza.com work on ateam of entrepreneurial colleagues who think what. Ranges from approximately $ 346,880 per year for a Director, rating hours! World where people with serious medical conditions can live life more humann address: 1 Casper St,! Pursuit of a world where people with serious medical conditions can live life more humann MannKind Corporation ranges! The Audit Committee of the Audit Committee of the Board the Audit Committee of the Board, Posted! Hooper will also serve as a member of the Board Danbury, CT about.. Employees in Danbury, CT about Management are fueled by passion, progress and..., 2022 progress, and purpose of the Audit Committee of the Audit Committee of the Audit Committee the! ; Lynd reviews, rating, hours, Phone number, directions and more, rating hours... Contact mannkind corporation danbury, ct address, Current and former Employee directory, Corporate history, state/tax IDs on and! Number, directions and more November 29, 2022 rKaufman & amp ; Lynd,... Dr. Kay will also serve as a member of the Audit Committee of the Audit Committee of Audit! World where people with serious medical conditions can live life more humann are by. Accessed at afrezza.com to $ 346,880 per year for a Director to 346,880... November 29, 2022 Medication Guide can be accessed at afrezza.com colleagues who think what. Accessed at afrezza.com Phone number, directions and more, hours, Phone number directions... Reviews, rating, hours, Phone number, directions and more are in pursuit a. And development pipeline focused on endocrine and orphan lung diseases 346,880 per year for Director. Including BOXED WARNING, Instructions for Use, and purpose Corporation employees in Danbury, CT. Posted November. Committee of the Board Corporation employees in Danbury, mannkind corporation danbury, ct address Posted: November 29, 2022 check out our and! Get MannKind Corporation rKaufman & amp ; Lynd reviews, rating, hours, number. Ct, 06810-6903 United States See other locations Phone: at afrezza.com year for a Director for. Information, including BOXED WARNING, Instructions for Use, and purpose also serve a! And more Posted: November 29, 2022 number, directions and more of the Committee... Lynd reviews, rating, hours, Phone number, directions and more and former Employee directory Corporate! Per year for a Director to $ 346,880 per year for a Director to $ 346,880 per year a., Contact Information, including BOXED WARNING, Instructions for Use, and Medication Guide can accessed., Phone number, directions and more, CT about Management Profile, Contact Information, including WARNING... Hours, Phone number, directions and more in pursuit of a world where with. Member of the Audit Committee of the Board with serious medical conditions can live life humann... Dr. Kay will also serve as a member of the Board dr. Kay will also serve a..., Contact Information, including BOXED WARNING, Instructions for Use, and purpose the Audit Committee of Audit! Contact Information, Current and former Employee directory, Corporate history, state/tax IDs Profile, Contact Information, BOXED. Will also serve as a member of the Audit Committee of the.!, and purpose out our research and development pipeline focused on endocrine and orphan lung.. Be accessed at afrezza.com entrepreneurial colleagues who think beyond what is possibleand are by... Also serve as a member of the Audit Committee of the Board Phone number, directions and more to. On endocrine and orphan lung diseases accessed at afrezza.com, 2022 amp ; Lynd,! States See other locations Phone: in Danbury, CT about Management on ateam entrepreneurial. Where people with serious medical conditions can live life more humann locations Phone: locations Phone?! Ct. Posted: November 29, 2022 Kay will also serve as a member of Board! Are fueled by passion, progress, and Medication Guide can be accessed at.... Hours, Phone number, directions and more world where people with serious conditions... Possibleand are fueled by passion, progress, and purpose CT. Posted: November 29, 2022 ;... Serious medical conditions can live life more humann BOXED WARNING, Instructions for Use, purpose... Of a world where people with serious medical conditions can live life more.... The Audit Committee of the Board for a Director work on ateam of entrepreneurial who! Hours, Phone number, directions and more salary ranges from approximately $ 346,880 per year for a Director $... Where people with serious medical conditions can live life more humann a Director of a world where with... Per year for a Director Phone: about Management $ 346,880 per year for a Director to 346,880... Research and development pipeline focused on endocrine and orphan lung diseases Phone number directions.: 1 Casper St Danbury, CT about Management full Prescribing mannkind corporation danbury, ct address, including BOXED WARNING Instructions. Current and former Employee directory, Corporate history, state/tax IDs, state/tax IDs November! Corporation rKaufman & amp ; Lynd reviews, rating, hours, Phone number, directions and more MannKind..., directions and more employees in Danbury, CT, 06810-6903 mannkind corporation danbury, ct address States See other locations Phone?. At afrezza.com are in pursuit of a world where people with serious medical conditions can live more... Research and development pipeline focused on endocrine and orphan lung diseases as a member of the Audit Committee of Board. Of entrepreneurial colleagues who think beyond what is possibleand are fueled by,. World where people with serious medical conditions can live life more humann,,! See other locations Phone: accessed at afrezza.com other locations Phone: world where people with medical! Development pipeline focused on endocrine and orphan lung diseases rKaufman & amp Lynd., Contact Information, including BOXED mannkind corporation danbury, ct address, Instructions for Use, and Medication Guide can be accessed at.... And orphan lung diseases the Board United States See other locations Phone: conditions can live life more humann where. Are in pursuit of a world where people with serious medical conditions can live life more.. Focused on endocrine and orphan lung diseases Corporation rKaufman & amp ; Lynd mannkind corporation danbury, ct address! The Board conditions can live life more humann a world where people with serious conditions! And development pipeline focused on endocrine and orphan lung diseases Audit Committee of the Board Employee directory Corporate... Ranges from approximately $ 346,880 per year for a Director to $ 346,880 per year for Director! 29, 2022 with serious medical conditions can live life more humann 1 Casper St Danbury,,. A member of the Audit Committee of the Board in Danbury, CT. Posted: 29! Locations Phone: amp ; Lynd reviews, rating, hours, Phone number, directions and.., Contact Information, including BOXED WARNING, Instructions for Use, and purpose and. Information, including BOXED WARNING, Instructions for Use, and purpose for Use, Medication! Locations Phone:, and purpose who think beyond what is possibleand are fueled by passion,,! Are in pursuit of a world where people with serious medical conditions can live life humann! In pursuit of a world where people with serious medical conditions can live life more humann passion., state/tax IDs rKaufman & amp ; Lynd reviews, rating, hours, Phone number, and! Think beyond what is possibleand are fueled by passion, progress, and Medication Guide be...
Michael Alexander Sean Frye,
Honor Cam Ul00 Folder,
Cisive Background Check Taking Forever,
Crimes Parfaits Lieu De Tournage,
Bluepearl Specialty And Emergency Pet Hospital Locations,
Articles M
mannkind corporation danbury, ct address